MarketCap
Facebook
X
TelegramAzurRx BioPharma, Inc. ROCE Ratio 2011-2026 | AZRX
Annual ROCE Ratio AzurRx BioPharma, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 1008280076442.74 | -319.32 | -300.23 | -335.97 | -150.13 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1008280076442.74 | -335.97 | 201656015067.42 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
40.11 | $ 16.64 | 1.59 % | $ 3.97 B |  USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Apellis Pharmaceuticals
APLS
|
14.97 | $ 19.84 | -1.59 % | $ 2.5 B | USA |
 |
Graybug Vision
GRAY
|
348.16 | - | -11.23 % | $ 9.65 M | USA |
 |
Axsome Therapeutics
AXSM
|
-188.87 | $ 164.97 | 0.56 % | $ 8.21 B | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.67 | -1.21 % | $ 1.1 B |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
BioLineRx Ltd.
BLRX
|
-104.07 | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
6.73 | $ 60.49 | 3.35 % | $ 11.6 B | USA |
 |
Athersys
ATHX
|
-531.85 | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-108.03 | - | - | $ 521 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 8.41 | -1.64 % | $ 1.39 B | Britain |
 |
Cabaletta Bio
CABA
|
-31.61 | $ 3.39 | 4.35 % | $ 3.96 M | USA |
 |
BridgeBio Pharma
BBIO
|
25.08 | $ 65.92 | 2.15 % | $ 12.6 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Codexis
CDXS
|
-87.44 | $ 1.06 | 8.16 % | $ 77.8 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-75.78 | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
80.97 | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Coherus BioSciences
CHRS
|
105.05 | $ 1.79 | 8.18 % | $ 169 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
453.99 | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-80.8 | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
552.16 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
552.16 | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-60.12 | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
-87.67 | $ 26.23 | 1.49 % | $ 702 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
Champions Oncology
CSBR
|
120.71 | $ 6.1 | 1.67 % | $ 83.3 M | USA |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Certara
CERT
|
1.98 | $ 7.25 | 0.14 % | $ 1.16 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
-59.93 | $ 0.81 | 9.12 % | $ 5.45 M | USA |